北海康成制药有限公司
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
CANbridge Announces NDA Acceptance of CAN108 (邁芮倍®/LIVMARLI®) for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis (PFIC) by China's National Medical Products Administration 2023-10-17 08:00
CANbridge Announces Full Enrollment Reached in the Core Part of The CAN103 Phase 2 Trial for Gaucher Disease in China 2023-10-16 13:38
CANbridge Announces Marketing Approval of CAN108 (/LIVMARLI®) in Taiwan for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome (ALGS) 2023-10-09 08:00
CANbridge to Participate in Two Investor Conferences in September 2023-09-06 16:06
CANbridge Announces Interim Financial Results and Corporate Updates for the Six Months Ended June 30, 2023 2023-08-31 15:15
1